Skip to main content
    G

    Gyre Therapeutics Inc. (GYRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.39
    +0.08 (+1.86%)

    Market Cap: $471.74M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Gyre Therapeutics Inc. (GYRE) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Gyre Therapeutics (GYRE) trades at 3.8x sales and 4.3x book value. Its P/B of 4.3x is above its 10-year median of 0.4x. Its forward P/E is 188.7x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E188.7x
    Price to sales3.8x
    Price to book4.3x
    PEGN/A
    FCF yield-5.3%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/B4.3xN/A0.4x
    Medians of month-end values through Oct 2026: 105 months (10-year).

    Valuation History

    Over the 7 of the 10 year ends shown that have a P/S, its P/S ranged from 1.0x in 2021 to 35.8x in 2017.

    Year endPriceP/EP/SP/B
    2025$7.0684.8x5.4x6.9x
    2024$12.10156.3x10.2x19.5x
    2023$25.69N/AN/AN/A
    2022$7.91N/A5.1x0.6x
    2021$3.60N/A1.0x0.1x
    2020$24.88N/A1.2x0.4x
    2019$26.85N/AN/A0.3x
    2018$31.10N/AN/A0.2x
    2017$53.77N/A35.8x0.6x
    2016$38.42N/A6.0x0.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GYRE

    What is GYRE's forward P/E ratio?

    Gyre Therapeutics has a forward P/E ratio of 188.7x.

    Is GYRE stock overvalued?

    GNG's valuation label for GYRE is Undervalued.

    What is GYRE's price to sales ratio?

    Gyre Therapeutics has a price to sales ratio of 3.8x.